Head-to-head · WeighScore
Aspen vs PauseRX
The verdict
PauseRX takes it — 68.5/100 to 58.4/100.
PauseRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aspen | PauseRX |
|---|---|---|
| WeighScore | 58.4/100 | 68.5/100 |
| Grade | C | C |
| Scorecard rank | #373 | #149 |
| Semaglutide | $279/mo (3-month plan, compounded) | $199/mo |
| Tirzepatide | $399/mo (compounded) | $249/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #373 · C
Strengths
- LegitScript-certified with an independently verifiable seal (#50306023) and HIPAA compliance — a strong trust signal for a compounded-GLP-1 telehealth
- Names its dispensing pharmacy: Red Rock Compounding Pharmacy, LegitScript-certified and NABP-accredited, licensed in 49 states plus DC
- Flat pricing at every dose ("same price at every dose, no surprises") plus free expedited shipping, so your cost won't rise as you titrate up
- Competitive prepay rates — compounded semaglutide as low as $179/mo (12-mo) and tirzepatide $299/mo — with zero interest and no credit check
- Money-back guarantee for qualifying patients who complete the full 28-week program without losing weight; available in all 50 states + DC
Where it loses points
- Compounded semaglutide and tirzepatide only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
- Even the "monthly" plan requires a 3-month commitment with three months of medication shipped and billed upfront — limited month-to-month flexibility
- Standing month-to-month pricing is steep ($279 semaglutide, $399 tirzepatide); the lowest rates require 6- or 12-month prepay
- The provider chooses semaglutide vs tirzepatide for you, so you can't freely pick your own molecule
- Registered as Aspen Health Systems LLC at a Sheridan, WY address; async model with no routine video visit
Graded #149 · C
Strengths
- Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
- Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
- Publishes the FDA compounded-medication disclaimer
- Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
- Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation
Where it loses points
- States served not listed — site claims nationwide, but you must contact support to confirm availability
- Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
- No named medical director (Beluga Health is the network, not a named MD)
- LegitScript certification number not shown — badge only, so no direct lookup
- Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.